Muscular Dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that GYLTL1B may be a candidate gene for muscular dystrophy and that its overexpression could compensate for the deficiency of both LARGE and other glycosyltransferases.
|
15661757 |
2005 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations.
|
21211798 |
2011 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression.
|
23223448 |
2013 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression.
|
23223448 |
2013 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression.
|
23223448 |
2013 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression.
|
23223448 |
2013 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, analysis of gene expression profiles of clinical samples in The Cancer Genome Atlas reveals negative correlation of LARGE2 and ZEB1 expression in various cancers.
|
25455932 |
2015 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the case of prostate cancer, one mechanism that contributes to αDG hypoglycosylation is transcriptional down-regulation of LARGE2 (GYLTY1B), a glycosyltransferase that produces the functional (laminin-binding) glycan on αDG, but the mechanism(s) underlying reduction of LARGE2 mRNA remain unclear.
|
25455932 |
2015 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the case of prostate cancer, one mechanism that contributes to αDG hypoglycosylation is transcriptional down-regulation of LARGE2 (GYLTY1B), a glycosyltransferase that produces the functional (laminin-binding) glycan on αDG, but the mechanism(s) underlying reduction of LARGE2 mRNA remain unclear.
|
25455932 |
2015 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, analysis of gene expression profiles of clinical samples in The Cancer Genome Atlas reveals negative correlation of LARGE2 and ZEB1 expression in various cancers.
|
25455932 |
2015 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our results suggest that LARGE2 is negatively regulated by Snail and/or ZEB1, revealing a mechanistic basis for αDG hypoglycosylation during prostate cancer progression and metastasis.
|
25455932 |
2015 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Reduced levels of GYLTL1B and ISPD mRNA associated with increased patient mortality and are the likely cause of αDG hypoglycosylation in ccRCC.
|
26220087 |
2015 |
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience.
|
29964129 |
2018 |
Vegetation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The objectives were to: 1) assess the macroaggregate distribution (proportional mass, class mass) and the SOC and particulate organic carbon (POC) stocks of extra-large (8-19mm), large (2-8mm) and small (0.25-2mm) macroaggregate size classes managed for two decades by NT, and 2) assess the recovery of SOC stocks in extra-large macroaggregates compared to adjacent native vegetation (Andropogon sp., Aristida sp., Paspalum sp., and Panicum sp.).
|
29122351 |
2018 |
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience.
|
29964129 |
2018 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Rotator cuff syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twenty-three patients undergoing repair of full-thickness large (2-tendon) or massive (3-tendon) rotator cuff tears augmented with a bioinductive collagen patch were enrolled in a prospective single-arm proof-of-principle study.
|
31150274 |
2019 |